Acta Scientific Pharmacology

Research Article Volume 2 Issue 10

Side Effects of Ivermectin, a Drug Recently Used to Treat Humans Suffering from the Covid-19; A Study on Ants as Models

Marie-Claire Cammaerts*

Independent Researcher, Retired from the Biology of Organisms Department, University of Brussels, Belgium

*Corresponding Author: Marie-Claire Cammaerts, Independent Researcher, Retired from the Biology of Organisms Department, University of Brussels, Belgium.

Received: September 03, 2021; Published: September 25, 2021


Ivermectin, a drug used for caring of persons suffering from parasitizes, has recently been found to potentially be used for treating the Covid-19 illness. Though the side effects of this drug used for treating parasitizes, those occurring when it is used for caring of persons suffering from the Covid-19 have not yet been sufficiently examined. Working on ants as models, we found that ivermectin decreases or largely impacts the individuals’ food consumption, activity, locomotion, muscles functioning, sensitive perception, social relationships, cognition, learning and memory. No adaptation occurred to these side effects; ants developed no dependence on ivermectin consumption. The drug lost its effect in 30 hours without showing any sudden decrease. Since this drug is very useful for treating parasitizes and may be shortly efficient for treating the Covid-19 illness or preventing contracting it, side effects similar to those found in ants should be cautiously examined in humans. The dosages should be medically defined, and lastly but not the least, the toxic ecological impact of this drug should be reduced.

Keywords: Activity; Cognition; Memory; Muscles Functioning; Social Relationships


  1. Caumes E., et al. “New indications for ivermectine”. La revue de Médecine Interne4 (2001): 379-384.
  2. Develoux M. “Ivermectine”. Annales de Dermatologie et de Vénéréologie6-7part1 (2004): 561-570.
  3. Bernigaud C., et al. “Bénéfice de l’ivermectine: de la galle à la COVID-19, un exemple de sérendipité”. Annales de Dermatologie et de Vénéréologie12 (2020): A194.
  4. Caly L., et al. “The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Antiviral Research 178 (2020): art n° 104787.
  5. Kory P., et al. “Review of the emerging evidence demonstrating the efficacity of ivermectin in the prophylaxis and treatment of COVID-19”. American Journal of Therapeutics3 (2021): e299-e318.
  6. Garegnani L.I., et al. “Misleading clinical evidence and systematic reviews on ivermectin for COVID-19”. EBM Opinion and Debate (2021).
  7. Sparsa A., et al. “Effets secondaires de l’ivermectine utilisée dans le traitement de la galle”. Annales de Dermatologie et de Vénéréologie (2005).
  8. Ducorps M., et al. “Effets secondaires du traitement de la loase hypermicrofilarémique par l’ivermectine”. Bulletin de la Société de Pathologie Exotique3 (1995): 105-112.
  9. Cammaerts MC. “Ants as biological models for studying effects of substances used by humans”. JSM Anatomy and Physiology 1003 (2016): 8.
  10. Cammaerts MC. “Some findings on ants as models, which should be considered for caring of humans”. MOJ Biology and Medicine5 (2017): 00027.
  11. Cammaerts MC. “Ants as models for examining potential adverse effects of products used by humans”. JSM Anatomy and Physiology1 (2018): 1016.
  12. Cammaerts MC. “Brief report of the effects of seven human drugs studied on ants as models”. MOJ Biology and Medicine2 (2019): 42-47.
  13. Cammaerts MC. “Harmful effects of humans’ environmental factors and drugs, and advices for a safer live; a study on ants as models”. World Journal of Pharmaceutical Sciences1 (2021): 34-45.
  14. Wehner R., et al. Biologie et physiologie animales. Eds. De Boeck Université, Thieme Verlag, Paris, Bruxelles (1999): 844.
  15. Lamounette B. Anatomie et PhysIologie animales. Hachette Bnf, Sciences (2014) 308.
  16. Russell WMS., et al. “The Principles of Humane Experimental Technique”. Johns Hopkins University (2014).
  17. Wolf FW., et al. “Invertebrate models of drug abuse”. Journal of Neurobiology 54 (2003): 161-178.
  18. Søvik E., et al. “Invertebrate models in addiction research”. Brain Behavior and Evolution 82 (2013): 153-165.
  19. Andre RG., et al. “Insect Models for Biomedical Research”. In: Woodhead AD, editor. “Nonmammalian Animal Models for Biomedical Research”. Boca Raton, FL: CRC Press (1989).
  20. Abramson CI., et al. “A social insect model for the study of ethanol induced behavior: the honey bee”. In Yoshida, R. (Ed.) “Trends in Alcohol Abuse and Alcoholism Research”. Nova Sciences Publishers, Inc., (2007): 197-218.
  21. Passera L., et al. “Les fourmis: comportement, organisation sociale et évolution”. Les Presses Scientifiques du CNRC, Ottawa, Canada (2005): 480.
  22. Cammaerts MC., et al. “Are ants (Hymenoptera, Formicidae) capable of self recognition?”. Journal of Sciences 7 (2015): 521-532.
  23. Cammaerts MC., et al. “Ontogenesis of ants’ cognitive abilities (Hymenoptera, Formicidae)”. Advanced Studies in Biology 7 (2015): 335-348 + synopsis: 349-350.
  24. Cammaerts MC., et al. “Ants’numerosity ability defined in nine studies”. Journal of Biology and Life Sciences1 (2020): 121-142.
  25. Cammaerts MC., et al. “Summary of seven more studies on numerosity abilities in an ant, four of them relating to human competence”. Journal of Biology and Life Sciences2 (2020): 296-326.
  26. Cammaerts MC., et al. “Non-numerical distance and size effects in an ant”. Journal of Biology and Life Sciences2 (2020): 13-35.
  27. Cammaerts MC., et al. “Weber’s law applied to the ants’ visual perception”. Journal of Biology and Life Sciences2 (2020): 36-61.
  28. Cammaerts MC., et al. “Ants can anticipate the following quantity in an arithmetic sequence”. Behavioral Sciences2 (2021): 13.
  29. Cammaerts MC., et al. “Reaction of ants to the simultaneous sight of two identical or different cues”. Trends in Entomology Soon in press.
  30. Cammaerts MC., et al. “Critical distance between two identical visual cues enabling their mental adding by an ant”. Trends in Entomology submitted.
  31. Cammaerts MC., et al. “Ethological and physiological effects of the recently most used analgesic, ibuprofen; a study on ants as models”. EC Pharmacology and Toxicology 4 (2018): 251-267.
  32. Cammaerts MC., et al. “Adverse effects of diclofenac observed on ants as models”. Acta Scientific Pharmaceutical Sciences3 (2019): 02-13.
  33. Cammaerts MC., et al. “Ethological and physiological effects of Sativex, a cannabis-based medicine, examined on ants as models”. Acta Scientific Pharmaceutical Sciences8 (2020): 63-84.
  34. Cammaerts MC., et al. “Amitriptyline: side effects of a largely used antidepressant evaluated on ants as biological models”. Acta Scientific Pharmaceutical Sciences5 (2021): 13-30.
  35. Siegel S., et al. “Nonparametric statistics for the behavioural sciences”. Singapore, McGraw-Hill Book Company (1989).
  36. Cammaerts MC., et al. “An easy and cheap software-based method to assess two-dimensional trajectory parameters”. Belgian Journal of Zoology 142 (2012): 145-151.
  37. Cammaerts MC. “Physical dependence on a substance occurs when the effect of this substance rapidly decreases after withdrawal”. JSM Anatomy and Physiology1 (2018): 1017.
  38. Prod’hom J., et al. “Lutte contre l'onchocercose par ivermectine: résultats d'une campagne de masse au Nord-Cameroun”. Bulletin de l'Organisation mondiale de la Santé4 (1991): 443-450.
  39. Chippaux JP., et al. “Apport de l’ivermectine dans le contrôle de l’onchocercose”. Cahiers Santé 5 (1995): 149-158.
  40. Prod’hom J., et al. “Ivermectin and reduction of the rate of infection of simulids in a human forest onchocerciasis focus”. Annales de Parasitologie humaine et compare6 (1987): 590-598.
  41. Boussinesq M. “Etude épidémiologique de l'onchocercose en zone de savane camerounaise: effets d'un traitement de masse par l'ivermectine”. Thesis, Biological Sciences, Parasitology, director: Brenques, J., Montpellier (1991).
  42. Chandre F., et al. “Action systemique de l'ivermectine sur Culex quinquefasciatus et Simulium squamosum”. Bulletin de la Société de Pathologie Exotique1 (1999): 71-72.
  43. Azzi A. “Ivermectine: pharmacologie, toxicologie, efficacité clinique et impact sur l'environnement”. Thesis, Direction de la programmation et des affaires économiques, Ministère de l’agriculture, du développement rural et des pêches maritimes (1994): 84-179.


Citation: Marie-Claire Cammaerts. “Side Effects of Ivermectin, a Drug Recently Used to Treat Humans Suffering from the Covid-19; A Study on Ants as Models". Acta Scientific Pharmacology 2.10 (2020): 40-53.


Copyright: © 2021 Marie-Claire Cammaerts. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US